d!NK Revenue and Competitors
Estimated Revenue & Valuation
- d!NK's estimated annual revenue is currently $1.3M per year.
- d!NK's estimated revenue per employee is $87,000
Employee Data
- d!NK has 15 Employees.
d!NK Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.2M | 3 | N/A | N/A | N/A |
#2 | $2.5M | 25 | N/A | N/A | N/A |
#3 | $0.6M | 13 | -24% | $14.3M | N/A |
#4 | $2.6M | 26 | N/A | N/A | N/A |
#5 | $0.5M | 11 | N/A | N/A | N/A |
#6 | $5.1M | 44 | N/A | N/A | N/A |
#7 | $0.2M | 3 | N/A | N/A | N/A |
#8 | $1M | 12 | N/A | N/A | N/A |
#9 | $1.1M | 11 | N/A | N/A | N/A |
#10 | $0.2M | 3 | N/A | N/A | N/A |
#11 | $0.9M | 10 | N/A | N/A | N/A |
#12 | $0.3M | 4 | N/A | N/A | N/A |
What Is d!NK?
N/A
Total Funding
15
Number of Employees
$1.3M
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
d!NK News
2022-04-20 - Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel
IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022
Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and
CIBMTR®
Presentations include an oral presentation by Wen Luo, Ph.D., ... NKTR-255 enhances anti-MCAM CAR NK cell cytotoxicity against Ewing sarcoma...
2022-04-17 - Latin AMAs 2022: The Best and Biggest Moments of the Night
NK said that, at this moment, her country is not just going through a ... D'Alessio and Nodal were each honored with two prestigious awards.
2022-04-13 - When killers become thieves: Trogocytosed PD-1 inhibits NK ...
5, A to D, y axis), showing that trogocytosis occurred in vivo. Strikingly, high levels of PD-1 were detected on the surface of NK cells only when tumor cells...
Other Companies in Aberfoyle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $17.3M | 95 | 9% | N/A |